{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:14:27Z","timestamp":1789330467667,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.atherosclerosis.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T19:57:46Z","timestamp":1617479866000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Adiposity and the development of dyslipidemia in APOE \u03b52 homozygous subjects: A longitudinal analysis in two population-based cohorts"],"prefix":"10.1016","volume":"325","author":[{"given":"Britt E.","family":"Heidemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-4050","authenticated-orcid":false,"given":"Frank J.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Kavousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eke G.","family":"Gruppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin PF.","family":"Dullaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-5714","authenticated-orcid":false,"given":"A. David","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-5223","authenticated-orcid":false,"given":"Frank LJ.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Koopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2021.04.001_bib1","first-page":"50","article-title":"Structure determines function, from atherosclerosis to Alzheimer's disease to AIDS","author":"Mahley","year":"2009","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2021.04.001_bib3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jama.298.11.1300","article-title":"Association of apolipoprotein E genotypes with lipid levels and coronary risk","volume":"298","author":"Bennet","year":"2007","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.ATV.8.1.1","article-title":"Apolipoprotein E polymorphism and atherosclerosis","volume":"8","author":"Davignon","year":"1988","journal-title":"Arteriosclerosis"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"e104608","DOI":"10.1371\/journal.pone.0104608","article-title":"Meta-analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction","volume":"9","author":"Xu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.atherosclerosis.2021.04.001_bib6","first-page":"14","article-title":"The impact of APOE genotype on survival: results of 38,537 participants from six population-based cohorts (E2-CHARGE)","author":"Wolters","year":"2019","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/10408363.2013.870526","article-title":"Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E","volume":"51","author":"Marais","year":"2014","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"10.1016\/j.atherosclerosis.2021.04.001_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clinbiochem.2017.11.010","article-title":"Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in epsilon2epsilon2 subjects","volume":"52","author":"Corsetti","year":"2018","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ijo.2014.105","article-title":"Group Ss. Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease","volume":"39","author":"Koopal","year":"2015","journal-title":"Int. J. Obes."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/hq0202.102919","article-title":"Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158--> Cys) homozygotes is associated with hyperinsulinemia","volume":"22","author":"de Beer","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clinbiochem.2018.06.009","article-title":"Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in epsilon2epsilon2 subjects by Bayesian network modeling","volume":"59","author":"Corsetti","year":"2018","journal-title":"Clin. Biochem."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s001090050227","article-title":"Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia","volume":"76","author":"Br\u00fcmmer","year":"1998","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/ejhg.2008.202","article-title":"The expression of type III hyperlipoproteinemia: involvement of lipolysis genes","volume":"17","author":"Henneman","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2021.04.001_bib14","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes","volume":"40","author":"Mahley","year":"1999","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.04.001_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jacl.2016.10.001","article-title":"Autosomal dominant familial dysbetalipoproteinemia: a pathophysiological framework and practical approach to diagnosis and therapy","volume":"11","author":"Koopal","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2021.04.001_bib16","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/hep.23916","article-title":"Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins","volume":"52","author":"Chen","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/oby.20682","article-title":"SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus","volume":"22","author":"Hassing","year":"2014","journal-title":"Obesity"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/hep.25580","article-title":"Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia","volume":"55","author":"Hassing","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cellsig.2018.12.001","article-title":"Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia","volume":"55","author":"Shrestha","year":"2019","journal-title":"Cell. Signal."},{"issue":"2\u20133","key":"10.1016\/j.atherosclerosis.2021.04.001_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0021-9150(85)90038-3","article-title":"Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment","volume":"57","author":"Janus","year":"1985","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2796.2001.00833.x","article-title":"Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity","volume":"249","author":"Hillege","year":"2001","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ki.2008.200","article-title":"Gender differences in predictors of the decline of renal function in the general population","volume":"74","author":"Halbesma","year":"2008","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.04.001_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10654-020-00640-5","article-title":"Objectives, design and main findings until 2020 from the Rotterdam Study","volume":"35","author":"Ikram","year":"2020","journal-title":"Eur. J. Epidemiol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/aje\/kwn209","article-title":"Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality","volume":"168","author":"Lambers Heerspink","year":"2008","journal-title":"Am. J. Epidemiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10654-017-0321-4","article-title":"The Rotterdam Study: 2018 update on objectives, design and main results","volume":"32","author":"Ikram","year":"2017","journal-title":"Eur. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood Institute scientific statement","volume":"21","author":"Grundy","year":"2006","journal-title":"Curr. Opin. Cardiol."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2021.04.001_bib27","first-page":"1421","article-title":"The separate and combined effects of adiposity and cardiometabolic dysfunction on the risk of recurrent cardiovascular events and mortality in patients with manifest vascular disease","volume":"100","author":"van der Leeuw","year":"2014","journal-title":"Heart (British Cardiac Society)"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2021.04.001_bib28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2337\/dc15-0684","article-title":"Body weight, metabolic dysfunction, and risk of type 2 diabetes in patients at high risk for cardiovascular events or with manifest cardiovascular disease: a cohort study","volume":"38","author":"Franssens","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2021.04.001_bib29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7326\/0003-4819-82-2-150","article-title":"Type III hyperlipoproteinemia: an analysis of two contemporary definitions","volume":"82","author":"Fredrickson","year":"1975","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacl.2020.06.004","article-title":"A simplified diagnosis algorithm for dysbetalipoproteinemia","volume":"14","author":"Paquette","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1161\/01.ATV.19.11.2722","article-title":"Severe hyperlipidemia in apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism","volume":"19","author":"Sijbrands","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2021.04.001_bib33","doi-asserted-by":"crossref","first-page":"e79473","DOI":"10.1371\/journal.pone.0079473","article-title":"Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects","volume":"8","author":"Matikainen","year":"2013","journal-title":"PloS One"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021001647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021001647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:45:37Z","timestamp":1758156337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915021001647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":33,"alternative-id":["S0021915021001647"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.04.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adiposity and the development of dyslipidemia in APOE \u03b52 homozygous subjects: A longitudinal analysis in two population-based cohorts","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}